You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌礼制药(01672.HK)附属候选药物获批开展中国临床试验
阿思达克 05-27 09:04
歌礼制药(01672.HK)公布,国家药品监督管理局(NMPA)已批准ASC42开展用於治疗非酒精性脂肪性肝炎(NASH)的临床试验。ASC42是旗下全资附属甘莱制药的候选药物。

ASC42是一款由甘莱完全自主研发、有望成为同类最佳的新型高效选择性非甾类法尼醇X受体(FXR)激动剂。ASC42口服片剂由甘莱专有制剂技术开发,具有室温下稳定的特点。ASC42既可作为单药使用,也可与甲状腺激素β受体(THR-β)激动剂ASC41或脂肪酸合成(酉每)(FASN)抑制剂ASC40联合使用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account